Palivizumab (MEDI 493) is a humanized IgG1 monoclonal antibody that targets the F protein of respiratory syncytial virus (RSV), a major cause of severe respiratory infections in infants and immunocompromised individuals. Palivizumab inhibits RSV fusion and entry into host cells, making it a critical research reagent for studying RSV pathogenesis, prophylaxis, and antibody-based antiviral strategies.
Palivizumab (MEDI 493) is a humanized IgG1 monoclonal antibody that targets the F protein of respiratory syncytial virus (RSV), a major cause of severe respiratory infections in infants and immunocompromised individuals. Palivizumab inhibits RSV fusion and entry into host cells, making it a critical research reagent for studying RSV pathogenesis, prophylaxis, and antibody-based antiviral strategies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
